A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen

Summary:
Tamoxifen remains the most common endocrine intervention prescribed to women with all stages of hormone receptor positive breast cancer or to decrease the incidence of the disease. The overall goal of this clinical trial is to determine whether variants in CYP2D (gene) influence progression free survival and other outcomes in women with metastatic breast cancer, and to explore the role of other genetic variants.

Eligibility and Treatment Plan:
Age 18 or older
Estrogen and/or progesterone receptor positive adenocarcinoma of the breast
Stage III/locally advanced or metastatic carcinoma of the breast where surgery is not possible

Please call for more information.